UBS maintains Bath & Body Works at Neutral, raises price target to $22 from $17

UBS kept its Neutral rating on Bath & Body Works but increased its price target to $22 from $17, suggesting a 4.4% upside from the Nov 12 close of $21.08. The new target represents a 29.4% increase.

Original reporting
Published Nov 13, 2026, 4:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 4:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
UBS maintains Bath & Body Works at Neutral, raises price target to $22 from $17 — source image
Decision brief

The 30-second read

$BBWIBullishMed
01

Why it matters

The higher target could trigger buying from investors following UBS's guidance.

02

Market read

Analyst target raise may influence short-term price action for BBWI.

03

What to watch

Potential supply chain constraints and competitive pressure are not addressed.

Relevance 6/10Novelty 6/10Timing: today

Background

UBS maintains a neutral rating but upgrades the price target, implying confidence in future earnings.

Company-level read

Ticker impact

$BBWIBullishMedium confidence
Context

UBS raised its price target for Bath & Body Works to $22 from $17, indicating a new bullish outlook.

Expected impact

likely upward pressure as traders price in the higher target

Evidence & confidence

Analyst upgrades often lead to short-term buying, especially when the new target is above the current price.

Market effects

May lift sentiment for the consumer discretionary sector.

US retail stocks could see modest gains.

Limited to US markets.

Counterpoint

The target raise may be premature if sales momentum stalls.

Key entities

  • Bath & Body Works

    US-listed retailer of personal care products.

  • UBS

    Financial services firm providing the rating and target.

Related articles

$BBYMed

Sportsman's Warehouse (NASDAQ:SPWH): Strongest Q2 Results from the Specialty Retail Group

Best Buy (BBY) reported Q2 revenue of $9.78B, up 3.6% YoY, beating estimates. Its stock rose 3.7% post-earnings. Dick's (DKS) reported $5.59B revenue, up 53.2% YoY, missing estimates. Its stock fell 24.7%. Sally Beauty (SBH) reported flat revenue of $935.5M, meeting expectations. Bath & Body Works (BBWI) reported $1.51B revenue, down 2.3% YoY, beating estimates. Its stock rose 4.8%.

$BBWIMed

How Investors May Respond To Bath & Body Works (BBWI) Stronger EPS Guidance Amid Softer Sales And Buybacks

Bath & Body Works (BBWI) reported Q2 2026 net income of $118M on $1.51B sales, completed a $382.93M share buyback, and updated guidance for a 4% to 2.5% decline in full-year sales but higher EPS. The company launched the Reserve Collection, focusing on product innovation. Analysts debate the stock's value, with projections ranging from $7.2B to $7.6B revenue by 2029.

$BBWIMedAI 8/10

Bath & Body Works, Inc. Q2 2027 Earnings Call Summary

Bath & Body Works reported Q2 2027 sales beat due to digital growth and expanded distribution. The company is shifting focus to enduring franchises and exiting the Home Care category. Digital sales improved, and management reinvested $35M in marketing. Guidance was narrowed, assuming macro pressures persist. Q2 results included an $80M tariff refund benefit. Management discussed sustainability of digital growth, store traffic strategies, and partnerships with Amazon and Ulta.

$BBWIMedAI 8/10

Bath & Body Works Q2 Earnings Call Highlights

Bath & Body Works reported Q2 sales of $1.1 billion, down 5.4% YoY, with direct-channel sales up 3% and international revenue up 24.9%. The company's digital business grew, and new product launches exceeded expectations. Bath & Body Works plans to exit its home-care category and expand distribution with Amazon and Ulta. It narrowed its full-year sales outlook to a decline of 2.5% to 4% and raised adjusted EPS guidance to $2.60 to $2.80.